In a significant leap forward for emergency medicine and biosecurity, Atlanta-based biotech firm Micron Biomedical has been awarded a $4.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID). The funding, allocated through the institute’s Radiation and Nuclear Countermeasures Program, is earmarked for the development of a pioneering, needle-free medical solution designed to treat Acute Radiation Syndrome (ARS). By marrying advanced, dissolvable microarray technology with potent pharmaceutical agents, the collaboration aims to replace cumbersome, traditional injection-based treatments with a simple, self-administered "patch" that could be a lifeline in the event of a radiological emergency.
The Core Innovation: A "Button" for Rapid Response
The centerpiece of this initiative is Micron’s proprietary microarray patch technology—a device that CEO Steven Damon describes as a simple, push-button applicator. Designed to be applied to the back of the wrist, the patch utilizes an array of microscopic needles that penetrate only the superficial layers of the skin. Because these needles do not reach deep nerve endings, the administration process is virtually painless.
Once pressed, the dissolvable microneedles release their therapeutic cargo directly into the skin, where the drug is absorbed into the systemic circulation. After the application is complete, the user simply discards the backing as standard, sharps-free waste. This mechanism eliminates the need for professional medical training, sterile injection environments, or the disposal of hazardous bio-medical sharps—all critical factors in high-stress, emergency scenarios.
Strategic Partnership with Connext
The $4.5 million contract centers on the integration of Micron’s delivery platform with a specific therapeutic agent: xempritolimod. Developed by the Korean clinical-stage biotechnology company Connext, xempritolimod is a TLR5 agonist. TLR5 agonists are highly regarded in medical research for their potential to stimulate the innate immune system, providing a robust defense mechanism against the cellular damage caused by high-dose radiation exposure.
By combining Connext’s potent therapeutic agent with Micron’s thermostable, easy-to-use delivery system, the partnership creates a product that can be stockpiled in warehouses indefinitely without the requirement for a cold chain—a major logistical hurdle for traditional vaccines and biologics.
Chronology of Development: From Georgia Tech to the Global Stage
The genesis of this technology traces back to the laboratory of Mark Prausnitz at the Georgia Institute of Technology. Prausnitz, a pioneer in the field of transdermal drug delivery, co-founded Micron Biomedical alongside Devin McAllister and Sebastien Henry to bridge the gap between academic innovation and commercial scalability.
- Foundational Years: The technology underwent rigorous refinement, transitioning from laboratory prototypes to a scalable manufacturing process. The team pioneered a unique micro-molding technique where liquid drug formulations are cast into templates and solidified under vacuum to eliminate air bubbles and ensure dose consistency.
- Proof of Concept: Early clinical trials, including a landmark study published in The Lancet, provided the clinical backbone for the platform. Testing the patches against multiple strains of influenza, researchers observed seroconversion rates that were not only competitive with traditional injections but, in specific instances, demonstrated superior immunological responses.
- The Pivot to Emergency Response: With the maturation of the platform, Micron pivoted toward high-impact applications. Partnerships with organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) further validated the technology’s potential for pandemic response, specifically regarding the "Disease X" threat model.
- July 2026 Milestone: The awarding of the NIAID contract on July 27, 2026, marks the most significant federal endorsement to date, signaling a shift from experimental development to a government-backed national security priority.
Supporting Data: Why Microarrays Matter
The argument for shifting away from needle-and-syringe delivery is backed by compelling data regarding both logistics and patient compliance. Micron’s internal and external testing highlights several key advantages:
Stability and Stockpiling
Unlike traditional biologics that often require precise refrigeration, Micron’s micro-molded, dried drug formulations remain stable at room temperature. This "thermostability" is the linchpin of the strategy for federal stockpiling. In a mass-casualty radiation event, the time required to mobilize refrigerated supplies could be the difference between life and death. The ability to deploy shelf-stable patches via conventional shipping methods to localized emergency centers is a logistical game-changer.
Clinical Efficacy
While the study published in The Lancet noted that differences between patch and injection were not statistically significant in every category, the data showed that the patch is an effective alternative. In the case of the influenza B strain, the patch achieved a 71% seroconversion rate at 28 days, compared to 32% for the injection. These findings suggest that the delivery system is not only more convenient but potentially more effective at eliciting an immune response for certain therapeutic agents.
Official Responses and Strategic Vision
In an exclusive discussion with Drug Discovery and Development, CEO Steven Damon emphasized that the primary challenge was not just the chemistry, but the infrastructure. "The key to improving that timeline was building out manufacturing," Damon noted. "We actually had to invent the equipment, and that equipment is being built domestically."
Damon’s vision is one of universal accessibility. During an emergency, the bottleneck is often the availability of trained medical professionals. By enabling self-administration, the Micron patch decentralizes the response. "If something happened, we’d be able to quickly get it to that location and to those people, and they’d be able to self-administer it. It would allow a fast response," he stated.
Furthermore, he highlighted the impact this could have on global health. In low-resource settings, where the cold chain is non-existent, these patches could be transported via bicycle or moped into remote villages, allowing for immunization without the need for a doctor or nurse. "They don’t need a doctor to administer it. A mom can administer it to her child," Damon added.
Implications for the Future of Healthcare
The implications of the NIAID-funded project extend far beyond radiation protection.
A Versatile Platform
While the current contract focuses on ARS, the platform is inherently modular. Once the FDA approves the manufacturing and delivery process for one drug, the regulatory pathway for others—such as vaccines or weight-loss medications—could theoretically be accelerated. Micron is currently pursuing a dual-track strategy: applying the delivery system to drugs that have already received regulatory approval, while simultaneously navigating the standard three-phase trial process for novel therapeutics.
Addressing the "Large-Dose" Limitation
Damon is transparent about the platform’s limitations, noting that it is not currently suitable for high-volume, large-dose therapeutics due to the physical constraints of the microscopic cavities. However, for vaccines, biologics, and small-molecule countermeasures like xempritolimod, the technology is highly efficient. As the company refines its manufacturing processes, it aims to expand the range of drugs the patch can accommodate.
A New Standard in Biosecurity
The focus on domestic manufacturing is a nod to modern biosecurity concerns. By building the capability to produce these patches within the United States, Micron is ensuring that the supply chain remains resilient against global disruptions. The goal is to move the first products to market by 2028, with the immediate focus being the validation of the platform for the FDA and the scaling of commercial production facilities.
Conclusion
The $4.5 million NIAID contract is more than just a research grant; it is a vote of confidence in the future of "distributed medicine." By prioritizing ease of use, stability, and patient comfort, Micron Biomedical is positioning its microarray technology as a critical component of the future public health infrastructure. As the company moves toward the 2028 market target, the successful integration of xempritolimod into the patch could redefine how we prepare for, and respond to, the most daunting threats to public safety.
About the Author
